Panther Biotech (PBYA) Makes Pre-IND Meeting Request with FDA Regarding TRF-DOX Development

October 10, 2016 7:05 AM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Panther Biotechnology, Inc. (OTC: PBYA) announced that a request for a Pre-IND (Investigational New Drug) meeting with the Division of Oncology Products 1 (DOP1) of the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration ("FDA") has been submitted. The purpose of the requested meeting is to obtain FDA's input regarding Panther's plans for the development of TRF-DOX, Panther's novel transferrin-doxorubicin conjugate for the treatment of platinum-resistant ovarian cancer. In preparation for the meeting, Panther is preparing a Pre-IND Package to be submitted to FDA that describes the information Panther intends on submitting in the TRF-DOX IND planned for submission in 2017. The IND is the regulatory vehicle that will allow for the initiation of clinical trials with TRF-DOX for the treatment of ovarian cancer.

FDA will specifically review Panther's manufacturing, preclinical pharmacology and toxicology, and clinical plans for TRF-DOX and provide specific feedback to Panther prior to the meeting.

TRF-DOX binds to transferrin receptors on tumor cells, inhibits cancer cell proliferation and causes cell death. TRF-DOX has been shown to exhibit increased cytotoxicity relative to unconjugated doxorubicin toward a variety of cancer cell lines and reduced cytotoxicity to normal cells. In addition to improvements in cytotoxicity and selectivity, TRF-DOX exhibits cytotoxic effects in many multidrug-resistant cells in vitro. Tumor targeting of doxorubicin to transferrin receptors on the cell membranes of tumor cells is intended to improve the therapeutic index of doxorubicin and to reduce the development of doxorubicin resistance. Panther is proposing to conduct an open label, multiple ascending dose study to investigate the safety, pharmacokinetics and preliminary efficacy of TRF-DOX in patients with platinum-resistant ovarian cancer.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Related Entities

Definitive Agreement

Add Your Comment